SBIR Phase II: Non-Chromatographic Method for the Purification of Viral Vectors — NSF Award to Isolere Bio, Inc (NC, $902,504)
The broader impact /commercial potential of this Small Business Innovation Research (SBIR) Phase II project is the creation of a scalable platform technology to deliver new therapies and vaccines through manufacturing viral vectors. This sector has been hampered by inefficient manufacturing methods designed for small m
| Award title | SBIR Phase II: Non-Chromatographic Method for the Purification of Viral Vectors |
|---|---|
| Award ID | 2132838 |
| Awardee | Isolere Bio, Inc |
| City | DURHAM |
| State | NC |
| Amount obligated | $902,504 |
| Principal investigator | Kelli Luginbuhl |
| Program | SBIR Phase II |
| Start date | 03/01/2022 |
| Abstract | The broader impact /commercial potential of this Small Business Innovation Research (SBIR) Phase II project is the creation of a scalable platform technology to deliver new therapies and vaccines through manufacturing viral vectors. This sector has been hampered by inefficient manufacturing methods designed for small molecules 10,000 times less complex than the current effort. The technology developed herein will provide a durable competitive advantage by offering “plug and play,” broad compatib |
| Source | NSF Awards |
$799/mo
Try NSFGrants →